Astellas bolsters oncology arsenal with $1.4 billion tivozanib deal
This article was originally published in Scrip
Astellas has taken another decisive step into oncology with a deal covering the ex-Asia global rights to AVEO Pharmaceuticals' lead product tivozanib that could eventually be worth around $1.4 billion to the US firm.
You may also be interested in...
New potential topical therapy in dermatitis space set to move towards Japan approval submission based on positive new results.
Japan approval for BTK inhibitor marks new indication but in a small niche market, while another clearance may help extend Latuda's commercial life.
Novel antibody-drug conjugate receives approval in Japan for second-line breast cancer, providing another push to Japanese firm’s strategic plan to build up its oncology operations.